<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: RE: Performance enhancement with selegiline</title>
<meta name="Author" content="Rafal Smigrodzki (rms2g@virginia.edu)">
<meta name="Subject" content="RE: Performance enhancement with selegiline">
<meta name="Date" content="2003-01-30">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>RE: Performance enhancement with selegiline</h1>
<!-- received="Thu Jan 30 07:27:18 2003" -->
<!-- isoreceived="20030130142718" -->
<!-- sent="Thu, 30 Jan 2003 09:36:22 -0500" -->
<!-- isosent="20030130143622" -->
<!-- name="Rafal Smigrodzki" -->
<!-- email="rms2g@virginia.edu" -->
<!-- subject="RE: Performance enhancement with selegiline" -->
<!-- id="BMEDJIBJGLNDOOANGIDLIEGFCJAA.rms2g@virginia.edu" -->
<!-- charset="iso-8859-1" -->
<!-- inreplyto="01a401c2c7d3$e991ab60$5b2093d0@MyPC" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Rafal Smigrodzki (<a href="mailto:rms2g@virginia.edu?Subject=RE:%20Performance%20enhancement%20with%20selegiline"><em>rms2g@virginia.edu</em></a>)<br>
<strong>Date:</strong> Thu Jan 30 2003 - 07:36:22 MST
</p>
<!-- next="start" -->
<ul>
<li><strong>Next message:</strong> <a href="1654.html">Max M: "Re: secret Saddam"</a>
<li><strong>Previous message:</strong> <a href="1652.html">scerir: "secret Saddam"</a>
<li><strong>In reply to:</strong> <a href="1620.html">gts: "Re: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="1655.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="1655.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#1653">[ date ]</a>
<a href="index.html#1653">[ thread ]</a>
<a href="subject.html#1653">[ subject ]</a>
<a href="author.html#1653">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
gts wrote:
<br>
<em>&gt; Rafal Smigrodzki wrote:
</em><br>
<em>&gt;&gt; gts wrote:
</em><br>
<em>&gt;&gt;  It's also an excellent antidepressant, especially when
</em><br>
<em>&gt;&gt;&gt; taken with DL-phenylalanine and B-6 (it increases levels of the
</em><br>
<em>&gt;&gt;&gt; natural mood enhancer phenylethylamine, and selectively inhibits the
</em><br>
<em>&gt;&gt;&gt; MAO-B enzyme that breaks down dopamine)
</em><br>
<em>&gt;&gt;
</em><br>
<em>&gt;&gt; ### How does it compare to MAOI's?
</em><br>
<em>&gt;
</em><br>
<em>&gt; It *is* a MAOI, but a unique and selective one. See below.
</em><br>
<em>&gt;
</em><br>
<em>&gt;&gt; It's not a coincidence that MAOI's are third-line antidepressants -
</em><br>
<em>&gt;&gt; they are too risky and not sufficiently effective compared to
</em><br>
<em>&gt;&gt; SSRI's, TCA's, and atypicals.
</em><br>
<em>&gt;
</em><br>
<em>&gt; Selegiline, is as I wrote, a *selective* inhibitor of MAO-B. There
</em><br>
<em>&gt; are two MAO enzymes, MAO-A and MAO-B. Conventional MAOI's inhibit
</em><br>
<em>&gt; both enzymes, and it is the inhibition of MAO-A that creates risks
</em><br>
<em>&gt; (MAO-A is necessary for the breakdown of tyramine, an amino acid
</em><br>
<em>&gt; found in certain foods like aged cheeses. Excessive levels of
</em><br>
<em>&gt; tyramine can lead to hypertensive crises, so those who take
</em><br>
<em>&gt; conventional MAOI's must watch their diet.) Selegiline at modest
</em><br>
<em>&gt; dosages inhibits only MAO-B and requires no dietary restrictions.
</em><br>
<p>### I know selegiline is a selective MAOI.
<br>
<p>I meant to write &quot;How does it compare to other MAOI's?&quot;
<br>
<p>In other words, since MAOI's suck, and selegiline is a MAOI, selegiline
<br>
sucks, too.
<br>
<p>Give me some data supporting the contention that selegiline is &quot;an excellent
<br>
antidepressant&quot;, compared to the SSRI's, TCA's, and atypicals I mentioned
<br>
above.
<br>
<p>-------------------
<br>
<p><p><em>&gt;
</em><br>
<em>&gt;&gt; . It enhances libido. It is
</em><br>
<em>&gt;&gt;&gt; neuroprotective; it almost certainly prevents or delays the onset of
</em><br>
<em>&gt;&gt;&gt; parkinson's disease in addition to being a treatment for it.
</em><br>
<em>&gt;&gt;
</em><br>
<em>&gt;&gt; ### Quote some studies giving us the &quot;almost certain&quot; feeling.
</em><br>
<em>&gt;
</em><br>
<em>&gt; Parkinson's Disease (PD) is characterized by the death of dopaminergic
</em><br>
<em>&gt; neurons. Numerous studies show that selegiline protects those
</em><br>
<em>&gt; neurons. In animal models of PD, the neurotoxin MPTP is used to cause
</em><br>
<em>&gt; PD. Selegiline protects against MPTP and numerous other neurotoxins
</em><br>
<em>&gt; and excitotoxins. It may also delay or prevent the onset of
</em><br>
<em>&gt; Alzheimer's Disease.
</em><br>
<em>&gt;
</em><br>
<em>&gt; Here are a few of many, many studies concerning the neuroprotective
</em><br>
<em>&gt; effects of selegiline:
</em><br>
<p>&lt;deleted for brevity&gt;
<br>
<p>### You have not quoted a single double-blind, placebo-controlled study
<br>
showing improved survival of PD patients on selegiline compared to standard
<br>
therapy. In other words, no class A evidence.
<br>
<p>All the studies you quote are in vitro, or reviews, and therefore at best
<br>
class C evidence, if at all. The abstracts mention alleged improvements in
<br>
survival on selegiline. This is hearsay, unless you provide the actual
<br>
quotations.
<br>
<p>There is conflicting class B evidence, with some observational studies
<br>
showing excess death in patients treated with selegiline (Lees AJ, and the
<br>
Parkinson's disease Research Group of the United Kingdom. Comparison of
<br>
therapeutic effects and mortality data of levodopa and levodopa combined
<br>
with selegiline in patients with early, mild Parkinson's disease. BMJ
<br>
1995;311:1602-7), others showing no effect at all (Parkinson Study Group.
<br>
Mortality in DATATOP: A multicenter trial in early Parkinson's disease. Ann
<br>
Neurol 1998;43:318-25).
<br>
<p>To be &quot;almost certain&quot; that selegiline delays or prevents PD is plainly
<br>
wrong.
<br>
<p>Rafal
<br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="1654.html">Max M: "Re: secret Saddam"</a>
<li><strong>Previous message:</strong> <a href="1652.html">scerir: "secret Saddam"</a>
<li><strong>In reply to:</strong> <a href="1620.html">gts: "Re: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="1655.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="1655.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#1653">[ date ]</a>
<a href="index.html#1653">[ thread ]</a>
<a href="subject.html#1653">[ subject ]</a>
<a href="author.html#1653">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Sun Feb 02 2003 - 21:26:03 MST
</em></small></p>
</body>
</html>
